Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977904371> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2977904371 endingPage "S1007" @default.
- W2977904371 startingPage "S1007" @default.
- W2977904371 abstract "Introduction: In the ELECT study, lanreotide depot, a long-acting somatostatin analog (SSA), was associated with significant improvement over placebo in the percentage of days with short-acting octreotide used as rescue medication for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor patients. In this subanalysis, we assessed the safety, tolerability, and efficacy of lanreotide depot 120 mg SC q4W in patients who had prior octreotide use. Methods: ELECT consisted of 16-week double-blind, 32-week open-label, and long-term extension phases. Adults with a histopathologically-confirmed gastroenteropancreatic neuroendocrine tumor (GEP-NET) or GEP-NET of unknown location with liver metastases and history of CS (flushing and/or diarrhea) were included. Patients were SSA-naïve or were responsive to conventional doses of octreotide LAR (≤30 mg q4W) or short-acting octreotide (≤600 μg daily), and were randomized to lanreotide depot 120 mg or placebo. Results: 64 patients (n=33 lanreotide; n=31 placebo) were previously treated with octreotide LAR (n=56), short-acting octreotide (n=24), or both (n=6). Mean age was 58.8 years, 45% were male, and 84% had been diagnosed ≥1 year before the study. Most treatment-emergent adverse events (TEAEs) were mild to moderate in nature. One patient receiving lanreotide experienced serious TEAEs (small intestinal obstruction and urinary infection). Nineteen patients (58%) receiving lanreotide experienced a TEAE; the most common included headache (18%), abdominal pain (12%), and nausea (9%).Twentytwo (71%) patients receiving placebo experienced a TEAE; the most common included abdominal pain (16%), nausea (16%), and dyspnea (13%). 52% of lanreotide patients experienced complete treatment success (0 to ≤3 days of rescue short-acting octreotide medication between weeks 12 and 15), vs 26% of placebo patients (RR = 1.996 [95% CI: 1.009, 3.950], p = 0.0471). Conclusion: A transition to lanreotide depot 120 mg in GEP-NET patients previously treated with octreotide LAR and/or SC was well tolerated and resulted in no new safety signals. The relative chance for achieving complete treatment success was 2 times greater with lanreotide than placebo." @default.
- W2977904371 created "2019-10-10" @default.
- W2977904371 creator A5000261865 @default.
- W2977904371 creator A5021719278 @default.
- W2977904371 creator A5031648774 @default.
- W2977904371 creator A5036188351 @default.
- W2977904371 creator A5037236309 @default.
- W2977904371 creator A5052418084 @default.
- W2977904371 creator A5081606866 @default.
- W2977904371 creator A5084480627 @default.
- W2977904371 creator A5088412188 @default.
- W2977904371 date "2015-10-01" @default.
- W2977904371 modified "2023-09-27" @default.
- W2977904371 title "Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy" @default.
- W2977904371 doi "https://doi.org/10.14309/00000434-201510001-02424" @default.
- W2977904371 hasPublicationYear "2015" @default.
- W2977904371 type Work @default.
- W2977904371 sameAs 2977904371 @default.
- W2977904371 citedByCount "2" @default.
- W2977904371 countsByYear W29779043712019 @default.
- W2977904371 countsByYear W29779043712021 @default.
- W2977904371 crossrefType "journal-article" @default.
- W2977904371 hasAuthorship W2977904371A5000261865 @default.
- W2977904371 hasAuthorship W2977904371A5021719278 @default.
- W2977904371 hasAuthorship W2977904371A5031648774 @default.
- W2977904371 hasAuthorship W2977904371A5036188351 @default.
- W2977904371 hasAuthorship W2977904371A5037236309 @default.
- W2977904371 hasAuthorship W2977904371A5052418084 @default.
- W2977904371 hasAuthorship W2977904371A5081606866 @default.
- W2977904371 hasAuthorship W2977904371A5084480627 @default.
- W2977904371 hasAuthorship W2977904371A5088412188 @default.
- W2977904371 hasConcept C126322002 @default.
- W2977904371 hasConcept C141071460 @default.
- W2977904371 hasConcept C142724271 @default.
- W2977904371 hasConcept C197934379 @default.
- W2977904371 hasConcept C204787440 @default.
- W2977904371 hasConcept C27081682 @default.
- W2977904371 hasConcept C2776297358 @default.
- W2977904371 hasConcept C2777433750 @default.
- W2977904371 hasConcept C2778375690 @default.
- W2977904371 hasConcept C2779066768 @default.
- W2977904371 hasConcept C2779609023 @default.
- W2977904371 hasConcept C2780580376 @default.
- W2977904371 hasConcept C2780955771 @default.
- W2977904371 hasConcept C2781025020 @default.
- W2977904371 hasConcept C2781151469 @default.
- W2977904371 hasConcept C2984496839 @default.
- W2977904371 hasConcept C71315377 @default.
- W2977904371 hasConcept C71924100 @default.
- W2977904371 hasConcept C90924648 @default.
- W2977904371 hasConceptScore W2977904371C126322002 @default.
- W2977904371 hasConceptScore W2977904371C141071460 @default.
- W2977904371 hasConceptScore W2977904371C142724271 @default.
- W2977904371 hasConceptScore W2977904371C197934379 @default.
- W2977904371 hasConceptScore W2977904371C204787440 @default.
- W2977904371 hasConceptScore W2977904371C27081682 @default.
- W2977904371 hasConceptScore W2977904371C2776297358 @default.
- W2977904371 hasConceptScore W2977904371C2777433750 @default.
- W2977904371 hasConceptScore W2977904371C2778375690 @default.
- W2977904371 hasConceptScore W2977904371C2779066768 @default.
- W2977904371 hasConceptScore W2977904371C2779609023 @default.
- W2977904371 hasConceptScore W2977904371C2780580376 @default.
- W2977904371 hasConceptScore W2977904371C2780955771 @default.
- W2977904371 hasConceptScore W2977904371C2781025020 @default.
- W2977904371 hasConceptScore W2977904371C2781151469 @default.
- W2977904371 hasConceptScore W2977904371C2984496839 @default.
- W2977904371 hasConceptScore W2977904371C71315377 @default.
- W2977904371 hasConceptScore W2977904371C71924100 @default.
- W2977904371 hasConceptScore W2977904371C90924648 @default.
- W2977904371 hasLocation W29779043711 @default.
- W2977904371 hasOpenAccess W2977904371 @default.
- W2977904371 hasPrimaryLocation W29779043711 @default.
- W2977904371 hasRelatedWork W1975657006 @default.
- W2977904371 hasRelatedWork W1975786744 @default.
- W2977904371 hasRelatedWork W1992285201 @default.
- W2977904371 hasRelatedWork W2004291258 @default.
- W2977904371 hasRelatedWork W2226335814 @default.
- W2977904371 hasRelatedWork W2401976036 @default.
- W2977904371 hasRelatedWork W2889516906 @default.
- W2977904371 hasRelatedWork W2963723926 @default.
- W2977904371 hasRelatedWork W3168492513 @default.
- W2977904371 hasRelatedWork W4366591216 @default.
- W2977904371 hasVolume "110" @default.
- W2977904371 isParatext "false" @default.
- W2977904371 isRetracted "false" @default.
- W2977904371 magId "2977904371" @default.
- W2977904371 workType "article" @default.